Healthcare resource utilization and costs among patients with heart failure with preserved, mildly reduced, and reduced ejection fraction in Spain
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1472-6963
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Healthcare resource utilization and costs among patients with heart failure with preserved, mildly reduced, and reduced ejection fraction in Spain ; volume:22 ; number:1 ; day:8 ; month:10 ; year:2022 ; pages:1-16 ; date:12.2022
BMC health services research ; 22, Heft 1 (8.10.2022), 1-16, 12.2022
- Urheber
-
Escobar, Carlos
Palacios, Beatriz
Varela, Luis
Gutiérrez, Martín
Duong, Mai
Chen, Hungta
Justo, Nahila
Cid-Ruzafa, Javier
Hernández, Ignacio
Hunt, Phillip R.
Delgado, Juan F.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12913-022-08614-x
- URN
-
urn:nbn:de:101:1-2022122621174241211564
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Escobar, Carlos
- Palacios, Beatriz
- Varela, Luis
- Gutiérrez, Martín
- Duong, Mai
- Chen, Hungta
- Justo, Nahila
- Cid-Ruzafa, Javier
- Hernández, Ignacio
- Hunt, Phillip R.
- Delgado, Juan F.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Semaglutide in patients with obesity and heart failure across mildly reduced or preserved ejection fraction
Phenogrouping heart failure with preserved or mildly reduced ejection fraction using electronic health record data
Transthyretin amyloidosis prevalence and characteristics in Korean patients with heart failure with preserved or mildly reduced ejection fractions
Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction
Real-world comparative effectiveness of ARNI versus ACEi/ARB in HF with reduced or mildly reduced ejection fraction
Predictors of mortality in heart failure patients with reduced or mildly reduced Ejection Fraction: The CASABLANCA HF Study
Prognostic impact of prior LVEF in patients with heart failure with mildly reduced ejection fraction
Genetic architecture of heart failure with preserved versus reduced ejection fraction
Increased epicardial adipose tissue is associated with left atrial mechanical dysfunction in patients with heart failure with mildly reduced and preserved ejection fraction
Urinary Marker Profiles in Heart Failure with Reduced Versus Preserved Ejection Fraction
Association between class of foundational medication for heart failure and prognosis in heart failure with reduced/mildly reduced ejection fraction
Guideline-directed medical therapy is similarly effective in heart failure with mildly reduced ejection fraction
Semaglutide in patients with obesity and heart failure across mildly reduced or preserved ejection fraction
Phenogrouping heart failure with preserved or mildly reduced ejection fraction using electronic health record data
Transthyretin amyloidosis prevalence and characteristics in Korean patients with heart failure with preserved or mildly reduced ejection fractions
Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction
Real-world comparative effectiveness of ARNI versus ACEi/ARB in HF with reduced or mildly reduced ejection fraction
Predictors of mortality in heart failure patients with reduced or mildly reduced Ejection Fraction: The CASABLANCA HF Study
Prognostic impact of prior LVEF in patients with heart failure with mildly reduced ejection fraction
Genetic architecture of heart failure with preserved versus reduced ejection fraction
Increased epicardial adipose tissue is associated with left atrial mechanical dysfunction in patients with heart failure with mildly reduced and preserved ejection fraction
Urinary Marker Profiles in Heart Failure with Reduced Versus Preserved Ejection Fraction
Association between class of foundational medication for heart failure and prognosis in heart failure with reduced/mildly reduced ejection fraction
Guideline-directed medical therapy is similarly effective in heart failure with mildly reduced ejection fraction
Semaglutide in patients with obesity and heart failure across mildly reduced or preserved ejection fraction
Phenogrouping heart failure with preserved or mildly reduced ejection fraction using electronic health record data
Transthyretin amyloidosis prevalence and characteristics in Korean patients with heart failure with preserved or mildly reduced ejection fractions
Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction
Real-world comparative effectiveness of ARNI versus ACEi/ARB in HF with reduced or mildly reduced ejection fraction
Predictors of mortality in heart failure patients with reduced or mildly reduced Ejection Fraction: The CASABLANCA HF Study
Prognostic impact of prior LVEF in patients with heart failure with mildly reduced ejection fraction
Genetic architecture of heart failure with preserved versus reduced ejection fraction
Increased epicardial adipose tissue is associated with left atrial mechanical dysfunction in patients with heart failure with mildly reduced and preserved ejection fraction
Urinary Marker Profiles in Heart Failure with Reduced Versus Preserved Ejection Fraction
Association between class of foundational medication for heart failure and prognosis in heart failure with reduced/mildly reduced ejection fraction